PAST PRESENTERS

 

October 30, 2009 Business Alliance Grubstake Breakfast Presenters

  

AlumniFidelity is an online fundraising company that enables schools to quickly roll out an unlimited number of volunteer-created fundraising pages. The company gives volunteer fundraisers the tools to promote the pages through email and social networks, and gives administrators the tools to customize, promote, and oversee the fundraising environment. 

AlumniFidelity has built for its clients a large and flexible data repository that captures all contact and demographic information from the sites' users. This data means that the platform readily delivers to its' clients potential new donors for follow up. Currently, new donor acquisition is the most expensive and difficult challenge for institutions. The end-game is a transformation of the way institutions relate to their supporters.

AlumniFidelity is seeking $350,000 to be used to enhance its fundraising platform by incorporating feedback from the firms first 30 clients, and to begin building a sales force.

Contacts:  David Andrukonis, Co-Founder, david@alumnifidelity.com, or Will Marlow, Co-Founder and President, will@alumnifidelity.com, 202-577-3350

Referred by John Casey, Mason Enterprise Center

 

   

DiaKine Therapeutics, Inc. is a clinical stage pharmaceutical development company that has in licensed and re-purposed its' lead drug for diabetes and related complications saving six (6) years in development time and cost. DiaKine's drug pipeline addresses both Type 1 and Type 2 diabetes in a $13B market segment expected to grow at a CGR of 14%. 

DiaKine's proprietary therapies address the root cause of the disease and have the potential to change diabetes treatment dramatically by blocking the inflammatory pathways that lead to the destruction of insulin-producing cells. Because of the drug's unique anti-inflammatory and immune modulating properties demonstrated in earlier studies, the company is now poised to advance into a major phase 2b final proof of concept trial for the treatment of "new onset" Type 1 diabetes to arrest the disease shortly after diagnosis. This will be a major value inflection point for the company. 

This therapeutic indication represents a huge medical need and the company is seeking $950K in funding to initiate an 18 to 24 month trial which will set the company up for an EXIT.

Contact:  Keith Ignotz, CEO & President, kignotz@diakine.com, 434-975-2001

Referred by Neil Cooper, Tech Acumen

  

NewVision Health offers "must have" interactive patient care software, NewVision, that enables hospitals to transform the patient experience by providing patient education, entertainment, and communications that enable caregivers to communicate with all patients - including those who do not speak English. 

For a typical 100-bed hospital that currently spends $3M a year delivering patient education, NewVision can save $600K+, reduce malpractice premiums, deductibles and settlements by $100K; and increase revenues by $125K+ providing an ROI in well under one year while increasing patient satisfaction and improved legal, regulatory, and industry compliance. NewVision supplements time-strapped caregivers in providing fully integrated, multimedia education 24x7 at the bedside.

NewVision Health is seeking $1 million to hire additional salespeople and staff; finish product development; install and support beta releases at Ft. Washington Medical Center, Calvert Memorial Hospital, and Washington Hospital Center; finalize partnership agreements; expand our website; launch marketing initiatives at major industry conferences, and sell and support NewVision.

Contact:  Dede Haskins, dhaskins@newvisionhealth.com, 703-421-4650

Referred by Anne Rosenblum, Fairfax County EDA

 

NuVue Therapeutics, Inc., is a privately held, drug/medical device company founded to address and solve unmet clinical needs in treating soft-tissue cancers. Through the development and use of an array of image-guided, interventional, site-specific delivery systems, NuVue has created a completely new and innovative way to treat these cancers.  Used in concert with its newly developed Targeted ChemoAblative Anti-Vascular Regimen of Therapy for the treatment of solid tumors, NuVue has developed a cryothermally assisted chemoablative alternative.  When this new CryoCool system is combined with proprietary ultrasound visualized, interventional, cryothermal, needle-like devices, NuVue can now target a tumor’s specific vascular market and deliver selected doses of different types of formulated drugs with pinpoint precision. 

These proprietary methods and devices insure the accurate and predictable diffusion of full therapeutic doses of drug(s), while they are being held and retained for therapeutic purposes within such targeted tissues.  NuVue has finally been able to overcome the deficiencies of Chemoablative Therapies through the development of its own proprietary methods encompassing the use of its interventional handheld, disposable devices, along with its specially designed Anti-Vascular Cancer Regimen needed to have successful therapeutic implementation.

The Company is now poised to capture rapid market penetration, upon its commercialization, immediately post funding. NuVue’s combined and innovative methods and regimen of therapies, with its proprietary therapeutic approach is expected to become a valuable neo-adjuvant and/or adjuvant alternative therapy to local, regional or systemic palliative therapies. 

NuVue Therapeutics is seeking $ 2,000,000 in equity to be used to: Complete product launch, immediately post funding, of its enhanced ColorMark™ biopsy and therapeutic ultrasound guided needles and delivery systems (Product 1); Complete design, conduct trials and obtain 510(k) for its second generation microencapsulated biopsy tissue markers (Product 2); Complete microencapsulation development, conduct trials and obtain NDA and 510(k) for its CryoChemoAblation Cancer Treatment System (Product 3), and finally continue to build organizational infrastructure, and assist with R&D, legal, operations, and raw materials and inventory for our first products manufactured.

Contact:  Roger Kolasinski, President/CEO, rskolasinski@ nuvuetherapeutics.com, 703-477-3000

Referred by Phillip Reilly, KOL, Bio-Med Instr.

 

 

OASIS HEALTHWARE is an Electronic Medical Record Software company established to develop, market, and sell EMR solutions exclusively for Medical Specialists. The specialty concept, content, and workflow of OASIS have been developed by Board Certified specialist physicians to address their unique practice requirements and to make efficient use of the time available for patient encounter documentation. This unique approach is protected by 2 patents.

OASIS has devoted years to crafting over 2000 modifiable, diagnosis-specific templates which streamline the documentation of the physical exam, x-ray findings, diagnoses and treatment plans. This intuitive "Diagnoses-based" approach saves physicians time and money and improves patient care.  OASIS will deliver its product and services directly to the Orthopedic community as well as through a select group of Value Added Resellers with expertise in medical specialty software. The initial offering is for Orthopedics with future releases scheduled for other medical specialties. 

OASIS is seeking $2,000,000 in equity to be used for marketing, sales, distribution, expansion, and future product development.

Contacts:  Dr. Thomas Walker, Chairman, t.walker@oasishr.com, or Art Medici, CEO, a.medici@oasishr.com, 703-713-3313

 

Referred by Art Medici, 9th Degree Advisors

 

 

October 30, 2009 Spotlight Tables

 

 

CYNCZ is based on a patent-pending suite of technologies that automatically synchronize and aggregate contact data and information across books contained in many industry-leading CRM, eMails, Mobile Communication device, Instant Messaging, and Social Networks. Via active synchronization methodologies, CYNCZ eliminates the need for subscribers to manually update and manage disparate contacts. 

  

Delivered via a Software-as-a-Service/Cloud (SaaS-Cloud) computing architecture CYNCZ is the only solution to provide patent-pending "rule- based two way" synchronization that permits users to choose what contacts to sync from what contact sources. CYNCZ also provides an innovative "roll back" feature allowing users to back-up and restore their contact or address books if data/device loss or account cancellation occurs. Once the user subscribes to CYNCZ and chooses which address book(s) or contact source(s) to synchronize, CYNCZ will automatically conduct scheduled or on-demand two-way synchronization and aggregation of contact data across various devices. If any contact information changes in any designated address book that change is automatically updated on all other selected contact sources and address books. CYNCZ is seeking $500,000 in equity to be used for product development, Testing, Marketing, IP and Patent, Office Space, Hardware and Software costs. 

Contact:  Jaya Pandey, Co-Founder, jaya@cyncz.com, 301-916-1315

Referred by: Rodney Loges, NetStrategies

  

Mylad Orthopedic Solutions is the proud developer of the OlecraNail™, the only minimally-invasive solution for elbow fractures cleared by the FDA that is implanted completely within the bone. This imperceptible, patent-pending device will minimize the need for a second surgery to remove the plates currently used to treat those fractures. The OlecraNail™ system is presently available in its limited launch, and has been implanted in seven surgeries during its first month of use. Mylad Orthopedic Solutions is backed by a management team whose individuals each have over 20 years of experience in the industry, and is utilizing a seasoned distribution network. Mylad is seeking $1.5M in funding to be used to build out inventory, marketing/sales, and distribution support for nationwide release in December. In a national $75M market, the company expects to generate revenues exceeding $9M by year 4, with an exit of $36M at that time. 

Contact:  Eve Edwards, eveedwards@myladortho.com, 703-738-6547

Referred by:Lisa Meyer, Celtic Capital Management

 

  

PluroGen Therapeutics is a burn, wound healing and skin care company with proven, superior, patented products focused to 3 multi-billion $ markets; $5.2 Advanced Wound Care, $6.0 billion Skin & Wound Cleansing and $120 billion Personal Skin Care. PluroGen already is selling, and has near-term and long-term products & multiple corporate partner relationships for each targeted market. The 4 platforms provide patented, unique physical, bioactive & multi-functional benefits not found in other products. PluroGen is seeking $1.25M in funding to be used and allocated as follows: $200K Sales & Marketing; $360K Manufacturing, Inventory, Product Extensions; $225K Regulatory & Clinical Support; $465K G&A (Legal, IP, Finance, Salaries, Consulting, Travel, and Office.

Contact:  Neal Kollar, President & CEO, nkollar@plurogen.com, 443-994-0101

Referred by: Andrea Alms, Spinner Technologies

  

  

June 12, 2009 Business Alliance Grubstake

Breakfast Presenters

 

HeMemics Biotechnologies, Inc. is a development and manufacturing company that is privately held. The company has proprietary technologies to dehydrate perishable biologics (proteins, cells, tissues, etc.) and has developed processes to extend shelf life while delivering cells in dried format for medical and non-medical applications. HeMemics is seeking $750,000 Convertible Debenture for facilities expansion, FDA approval, to support staff expansion, and for business development and marketing.

 

Contact: Isaac Gadsden, VP Mkt and Business Dev, ilgadsden@hememics.com, 301-560-0415

 

NextGen filed patent applications in December 2008 for an Integrated Stand off Detection System (ISOD) for the detection of explosives and narcotics. This is a clean slate technology. The source of iMars (Integrated Multi Application Radiation System) is the underpinning technology used in this invention. iMars generates Millimeter-wave, THz radiation, and Fast Neutrons.

 

Detection systems, gates and wands, have been counter terrorism’s most ubiquitous tools for many decades. A gradual phase out of these tools is taking place in favor of new technologies that will be able to detect a larger spectrum of threats faster, more accurately, and for less money. At the same time, deaths by IED’s and security at airports have become a major security concerns. These threats will continue to grow and countering them has become the focus of much effort. Up until now, there has not been a device that detects explosives FROM A SAFE DISTANCE.

 

The source will send out a beam of Terahertz or Microwave rays for the detection and identification of suspect. The detector measures the rays reflected off the target and checks them against a database of spectroscopic signatures resulting in the identification of the target.  Backpack versions detect explosives from distances of up to 50 meters. Vehicle portable devices can have a range of 500 meters.  Applications include airport security, IED detection, building and border security, and law enforcement, just name a few.

In order to develop the production version of this device, NextGen is seeking about $5,000,000 dollars in funding. The funds will be used for miniaturizing, software development, integration, marketing, and sales.

  

Contact: Ross Shariati, President, rs@picknextgen.com, 703-652-8447

 

Parabon NanoLabs, Inc., (PNL) develops novel therapeutics, bioweapons sensors, DNA biometrics, and other nano-enabled products made possible by its proprietary technology for engineering the self-assembly of designer macromolecules using synthetic DNA. Strands of DNA are programmed with sequences that self-assemble into arbitrarily shaped molecular breadboards that can be richly functionalized and mass-produced – feats not achievable with any other nanotechnologies. 

  

The computational complexity of determining effective DNA design sequences has stymied its widespread use for nano-assembly. Over the past four years, PNL has addressed this critical need by advancing not only their supercomputing tool, but also the nano-fabrication methods required for rapid engineering of nano-enabled solutions, giving the Company a strong competitive advantage in a vast market. PNL’s technology is being validated through SBIR wins and strategic pharmaceutical and system integrator alliances. PNL seeks $2,000,000 for product development, marketing and sales.

 

Contact: Steve Armentrout, Founder and President, sarmentrout@parabon.com, 703-689-9689 x207

Referred by: Paula Armentrout, Parabon

 

 

TRX Systems makes personal pin-point location devices that work anywhere, even when GPS is unavailable. The technology uses ad-hoc sensor networks to provide tracking, monitoring and data communications abilities required for applications including real-time first responder location and blue force tracking. The system is completely mobile and does not require any pre-installed infrastructure on any building in order to accurately locate personnel. Our superior technology, experienced management team and prestigious customer advisory board give us a significant advantage in the first responder market, which will be our initial focus. We have completed successful demonstrations within the fire services community, anxious to see our product in the market. TRX is seeking $1,500,000. With funds raised from equity investment we will hire additional staff including product management, engineering, sales, customer service and management. We will also formalize partnership arrangements with distributors and invest in fire trade shows for mass marketing. 

Contact: Karina Drees, CFO, karina@trxsystems.com, 301-313-0053

 

Referred by: Innovectra

 

 

June 12, 2009 Grubstake Breakfast

Spotlight Tables

  

Endtone’s patent pending disconnect tone product transforms the end of wireless calls into multimedia, entertaining and public events. Estimated at just over $3 billion USD, the disconnect tone market makes Endtone an excellent investment opportunity and provides the company and its investors with many low risk, high return exit alternatives. 

 

What is a disconnect tone? Similar in many ways to ringtones (a $7 billion USD market in 2008), disconnect tones are heard and seen when wireless users end calls or when calls are accidentally dropped.

 

Our short demonstration video is an excellent way to see and hear all of the disconnect tone benefits: http://www.youtube.com/watch?v=6YSeHqCUHw8

 

Endtone is aggressively adding new revenue streams. Already available in India, pending disconnect tone launches include Russia, Nokia’s OVI Store, and BlackBerry’s App World. 

 

Endtone seeks $300,000. These new funds will drive new version development (Apple’s iPhone, Palm’s webOS Mobile, etc.) and deliver new revenue opportunities.

 

Contact: Brock Muir, President, brock.muir@endtone.com, 202-498-9222

 

  

SCIT Labs is developing and commercializing threat independent cyber security solutions for the government and commercial markets. Today’s business imperatives require connections to the internet. This interconnectivity makes today’s businesses, missions and individuals vulnerable to Cyber attacks. Current Cyber Security threats are becoming more complex and pervasive. 285 million records were compromised in 2008 (Verizon). Over 500,000 web sites were successfully compromised in 2008 (Breach Security); Malicious intrusions were up 40% in 2008 (U.S. CERT). Currently, Symantec generates over ten thousand threat signatures a day, compared to 1000 per week just a few years ago. Obviously, threat specific, signature and a priori information based approaches do not eliminate intrusions. Self Cleansing Intrusion Tolerance (SCIT) technology provides an inexpensive, threat independent solution to contain losses for server based IT functions. SCIT is seeking $1.5 to $2.0 M to go towards: product development (30%), Sales engineering and support (30%), and marketing/sales/business development/licensing (40%).

 

Contact:  Arun Sood, CEO, asood@scitlabs.com, 703-347-4494

Referred by: Lloyd Griffiths, George Mason University

 

 

March 19, 2009 Business Alliance Grubstake

Breakfast Presenters

  

ChicksWithKidz (CWK) developed a patent pending electronic device to aid in monitoring medications, diet, sleep patterns and other daily routines. The product caters to 4 distinct market segments: Infant care, older child/adult/geriatric care, pet care and data mining. The initial product launch focuses on the infant care market, specifically targeting institutions where trials are scheduled to begin. Features include alarms to notify parents and caregivers when it is time to medicate, with the ability to program the names and dose times for up to twelve medications. Additionally, the device tracks feedings by breast or bottle as well as nap schedules and can be uploaded to the PC to store data, monitor trends and share information with pediatrician. The device stores up to 5 days of data allowing working parents with the press of a button, to scroll through the information upon returning home from work or a night away. The BizzyBee also has a complete line of accessories. CWK is seeking $1 million for continued marketing and manufacturing.

 

Contact:  Kirsten Knull: CEO, kirsten@chickswithkidz.com, 757-880-1118

 

Eye Controls designs and manufactures the patent-pending SafeMatch® iris identification system. Government and the healthcare industry will spend $150-$250 Billion over the next four years to implement electronic medical records nationwide. These systems cannot operate effectively without associated identification systems that link patients to the correct record. Also, positive ID is needed for staff for access to patient records and e-prescribing functions. There is a $5 Billion market for these medical identification systems. The Iris, the colored ring in the eye, is more unique than a fingerprint and U.S. government studies confirm that iris ID is the most accurate biometric technology. The company's products provide rapid log-in and access for staff, and prevent medical and recordkeeping errors by positively matching patients to their electronic medical records, medications, and procedures. The company's products deliver safe, fast, cost-effective, accurate ID for a wide range of medical and other applications. Eye Controls is seeking $250,000 equity, debt, or blended funding in the first quarter. The company is seeking  $2,000,000 equity in the second quarter. The proceeds will support manufacturing operations, including tooling costs and establishing inventory to fill current orders.

 

Contact:  Evan Smith: CEO, esmith@eye-controls.com, 703-615-3555

 

 

Mingle 360 is a social connectivity platform that makes it easier for consumers to safely connect with each other, with vendors and with product of interests, (the fundamental concept of tagging.) Our patent-pending technology makes it easy to create physical world connections with a single click and the result is a great leap forward in extending the Internet into life's day to day activities. The value to the user is convenience, novelty, and enhanced social connectivity and for the sponsor building trust relationships with prospects in a social media environment. Offered as a service to event organizers, the Mingle360 solution greatly enhances attendee networking at the event, surpassing business cards with up to date contact information and even facial recognition. It creates 'buzz' and excitement at the event and helps differentiate the organization from the competition. Event planners can also implement the lead retrieval technology using the countertop unit called the MingleStation. All in all, Mingle360 is the easiest way to turns real-world conversations into online connections and to produce dramatically more valuable networking events. Mingle 360 is seeking $2M equity or debt. The funds will be used for sales and marketing infrastructure, key hires in tradeshow/convention marketplace, completion of product development, logistics preparation for rapid growth, international filings for core patents already filed in the U.S., and to create additional IP (patents, trade secrets, publications, etc.) directed toward leverage in key partnerships and potential M&A opportunities.

 

Contact: Dan Coffing: CEO, dcoffing@mingle360.com, 703-425-0402

   

 

Pixelligent Technologies, LLC is a nanotechnology company. Pixelligent's leading innovation is centered around lithographic applications used in integrated circuit design. Lithography has been the main driver behind Moores Law.  Pixelligent's principal nanotechnology product is a liquid-based lithographic solution, which contains dispersed nanocrystals that act to focus light. This improves the resolution which enables more transistors to be printed on each chip. This solution will be used in the production of semiconductors to increase the processing capacity of computer chips. Pixelligent is seeking $700,000 equity. $900K has been raised in this round to date. 

 

The funds will go to product development, working capital, and to retire debt.

 

Contact:  Craig Bandes:CEO, cbandes@pixelligent.com, 301-405-9284

 

 

SitScape empowers business users to "quickly access important information matters to them at any situational moment - at a glance". SitScape's enterprise software product enables business users to assemble situational business dashboards in minutes through on-demand componentization and user interface virtualization of the disparate enterprise Web applications and external Web sites. This can all be done in the style of self-service in minutes with zero programming. SitScape's product can deliver business value to the end-users 100x faster comparing to traditional approaches, and requires zero change to any existing IT infrastructure. It ensures that visible business value is quickly delivered to end users in minutes. It can significantly speed-up time-to-market, reduce IT dependency, save cost, and enhance business agility and decision making. Sitscape is seeking $1,500,000 equity. The funds will go to marketing and sales.

Contact:  Kevin Yin: CEO, kyin@sitscape.com, 571-432-8130

 

 

March 19, 2009 Grubstake Breakfast

Spotlight Tables

 

 

Dalos BioPharma is a products-based company specializing in bacterial and viral infections of the skin. Dalos products are naturally-occurring botanical products, derived from a proprietary single source. Dalos has initially targeted the following therapeutic areas in skin disease: 1) MRSA (Methicillin-resistant Staphylococcus aureus) and other Staphylococcus-related skin infections; and 2) Molluscum contagiosum and other viral diseases of the skin. The lack of suitable therapies in these disease states lend themselves to rapid growth in the use of the products, both in the United States and internationally. We are also targeting 3) Eczema, Atopic Dermatitis, and other inflammatory skin diseases (human and veterinary applications);and 4) Consumer Products (liquid hand soap, body wash, shampoo, disinfectants). We are aware of activity in even more areas, but will not move into those areas until suitably capitalized. The initial indications chosen by Dalos, MRSA and Molluscum, represent large, open and profitable markets for these products. Dalos BioPharma is seeking up to $2M in traunches in the form of debt, equity or a combination. The funds will go to marketing/sales, product formulation and manufacture, intellectual property expansion, and marketing trials.

 

Contact:  Gary Pekoe: CEO, gpekoe@dalosbio.com, 757-631-2114

 

 

Turiss, LLC provides information security services and software that prevents cyberfraud. Turiss provides cutting edge cyber-intelligence reports and alerts to financial institution clients based on intelligence generated by its civil intelligence network. It likewise provides security analysis of IT infrastructure, incident response services for data breaches, and high-end computer forensic consulting to clients, often in support of litigation. Finally, Turiss has used its expertise and experience to develop software applications to combat the latest generations of cyber-fraud attacks.

Contact:  Richard Kelsey, rich.kelsey@turiss.com, 703-880-4279